ACADIA Pharmaceuticals Inc. Stock News

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020, at 4:40 p.m. Eastern Time.

A strong Q1 performance set the tone, but commitment to its strategy will be key to drive the stock higher.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Busine

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3

The

Q1 2020 ACADIA Pharmaceuticals Inc Earnings Call

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous